Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
| ▸ | NMT2 | O60551 | 1/20 | 0.37 |
| ▸ | NMT1 | P30419 | 1/20 | 0.37 |
| ▸ | FURIN | P09958 | 5/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.36 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30435145 | 0.90 | NPY4R (0.43) | SMN1; SMN2NMT2NMT1 | |
| SCHEMBL30477361 | 0.85 | NPY4R (0.42) | SMN1; SMN2FURINEPHX2NOD1 | |
| SCHEMBL29385639 | 0.85 | C3AR1 (0.45) | C3AR1SMN1; SMN2CTDSP1FURINSHMT1 | |
| SCHEMBL31064825 | 0.84 | NPY4R (0.43) | NMT2NMT1NOD1 | |
| SCHEMBL30089322 | 0.84 | SLC15A2 (0.47) | NMT2NMT1FURINCTSL | |
| SCHEMBL2113661 | 0.82 | C3AR1 (0.56) | C3AR1CTDSP1EPHX2SHMT1MEN1 | |
| SCHEMBL27860339 | 0.82 | C3AR1 (0.56) | C3AR1CTDSP1EPHX2SHMT1MEN1 | |
| SCHEMBL31665970 | 0.81 | NMT2 (0.41) | C3AR1NMT2NMT1FURINQRFPR | |
| SCHEMBL22698746 | 0.81 | FURIN (0.38) | C3AR1NMT2NMT1FURINCTSL | |
| SCHEMBL22524830 | 0.81 | C3AR1 (0.41) | C3AR1CTDSP1NMT2NMT1QRFPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4114417-A2 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2023-01-11 | — | — | EP | claimed |
| US-20220257789-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | EXELIXIS, INC. | 2022-08-18 | — | — | US | claimed |
| EP-3994150-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | Iconic Therapeutics, Inc. (US) | 2022-05-11 | — | — | EP | claimed |
| CN-114222752-A | Anti-tissue factor antibody-drug conjugates and related methods | 伊科尼克治疗公司 | 2022-03-22 | — | — | CN | claimed |
| US-20260042847-A1 | CYSTEINE ENGINEERED ANTIBODY CONSTRUCTS, CONJUGATES AND METHODS OF USE | ZYMEWORKS INC (CA) | 2026-02-12 | — | — | US | disclosed |
| US-20260028420-A1 | ANTI-TUMOR ANTIBODIES | IMMUNOME INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260022193-A1 | METHODS OF TREATMENT USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 | ZYMEWORKS BC INC (CA) | 2026-01-22 | — | — | US | disclosed |
| US-20250339552-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC (CA) | 2025-11-06 | — | — | US | disclosed |
| US-12435157-B2 | Methods of using a bispecific antigen-binding construct targeting HER2 for the treatment of biliary tract cancers | ZYMEWORKS BC INC. (CA) | 2025-10-07 | — | — | US | disclosed |
| US-12433952-B2 | Antibody-drug conjugates targeting folate receptor alpha and methods of use | ZYMEWORKS BC INC. (CA) | 2025-10-07 | — | — | US | disclosed |
| US-20250295799-A1 | ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2025-09-25 | — | — | US | disclosed |
| US-20250276077-A1 | EPHA2 ANTIBODIES | IMMUNOME INC (US) | 2025-09-04 | — | — | US | disclosed |
| EP-4114417-A2 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2023-01-11 | — | — | EP | disclosed |
| WO-2022228422-A1 | BISPECIFIC ANTIBODY-DRUG CONJUGATE | 轩竹生物科技股份有限公司 | 2022-11-03 | — | — | WO | disclosed |
| US-20220257789-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | EXELIXIS, INC. | 2022-08-18 | — | — | US | disclosed |
| EP-3994150-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | Iconic Therapeutics, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| US-20220133903-A1 | METHODS OF USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 FOR THE TREATMENT OF BILIARY TRACT CANCERS | ZYMEWORKS BC INC. (CA) | 2022-05-05 | — | — | US | disclosed |
| EP-3976098-A1 | METHODS OF USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 FOR THE TREATMENT OF BILIARY TRACT CANCERS | Zymeworks Inc. (CA) | 2022-04-06 | — | — | EP | disclosed |
| CN-114222752-A | Anti-tissue factor antibody-drug conjugates and related methods | 伊科尼克治疗公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114025795-A | Methods of treating biliary tract cancer using bispecific antigen-binding constructs targeting HER2 | 酵活有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276077-A1 | EPHA2 ANTIBODIES | EPHA2, EPHB2, EPHA1 | C3AR1 56/4885SMN1; SMN2 3936/4885CTDSP1 3603/4885 |
| US-20250339552-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | FOLR1, FOLR2, DHFR | C3AR1 417/4885SMN1; SMN2 3924/4885CTDSP1 2498/4885 |
| US-20260042847-A1 | CYSTEINE ENGINEERED ANTIBODY CONSTRUCTS, CONJUGATES AND METHODS OF USE | BCR, CLTC, CARS1 | C3AR1 1847/4885SMN1; SMN2 4437/4885CTDSP1 1557/4885 |
| US-12433952-B2 | Antibody-drug conjugates targeting folate receptor alpha and methods of use | FOLR1, FOLR2, DHFR | C3AR1 417/4885SMN1; SMN2 3924/4885CTDSP1 2498/4885 |
| US-20260022193-A1 | METHODS OF TREATMENT USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 | IGSF11, ERBB2, PDCD1LG2 | C3AR1 1977/4885SMN1; SMN2 3802/4885CTDSP1 721/4885 |
| US-20220133903-A1 | METHODS OF USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 FOR THE TREATMENT OF BILIARY TRACT CANCERS | AURKC, AURKB, BSG | C3AR1 1264/4885SMN1; SMN2 4772/4885CTDSP1 2339/4885 |
| US-20250295799-A1 | ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USE | B3GAT3, GALNT3, GOLGA3 | C3AR1 584/4885SMN1; SMN2 3316/4885CTDSP1 3851/4885 |
| US-20220257789-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | F3, F13B, TFPI | C3AR1 106/4885SMN1; SMN2 3706/4885CTDSP1 1884/4885 |
| US-12435157-B2 | Methods of using a bispecific antigen-binding construct targeting HER2 for the treatment of biliary tract cancers | AURKC, AURKB, BSG | C3AR1 1264/4885SMN1; SMN2 4772/4885CTDSP1 2339/4885 |
| US-20260028420-A1 | ANTI-TUMOR ANTIBODIES | B4GALT1, ST6GAL1, GALNT3 | C3AR1 1473/4885SMN1; SMN2 3544/4885CTDSP1 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.